Search

Your search keyword '"Dolmetsch, Ricardo"' showing total 385 results

Search Constraints

Start Over You searched for: Author "Dolmetsch, Ricardo" Remove constraint Author: "Dolmetsch, Ricardo"
385 results on '"Dolmetsch, Ricardo"'

Search Results

1. Harnessing rare variants in neuropsychiatric and neurodevelopment disorders—a Keystone Symposia report

4. Neuronal defects in a human cellular model of 22q11.2 deletion syndrome

5. A framework for the investigation of rare genetic disorders in neuropsychiatry

7. The 22q11.2 region regulates presynaptic gene-products linked to schizophrenia

8. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

10. Developmental convergence and divergence in human stem cell models of autism spectrum disorder

11. Translating genome-wide association findings into new therapeutics for psychiatry

12. 16p11.2 Deletion Syndrome Mice Display Sensory and Ultrasonic Vocalization Deficits During Social Interactions

13. Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons

14. Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes

15. Alteration in basal and depolarization induced transcriptional network in iPSC derived neurons from Timothy syndrome

16. Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome.

17. Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells.

18. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome

19. Patient Brain Organoids Identify a Link between the 16p11.2 Copy Number Variant and the RBFOX1 Gene

22. Calcium Regulation of Neuronal Gene Expression

23. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

24. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency

25. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

26. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

27. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

31. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy

32. Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

33. Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

37. H49 The Huntington’s disease quality of life battery for carers (HDQOL-CS): evidence from the Huntington’s disease burden of illness (HDBOI) study for Europe

38. F64 Suicidal ideation and sleep disturbances by disease stage: evidence from the Huntington’s disease burden of illness (HDBOI) study for europe (EU5)

44. A framework for the investigation of rare genetic disorders in neuropsychiatry

47. NEURODEVELOPMENT: CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency

49. Patient brain organoids identify a link between the 16p11.2 copy number variant and the RBFOX1 gene

50. Gabapentin Receptor α2δ-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis

Catalog

Books, media, physical & digital resources